Dendreon

Seal Beach, United States Founded: 1992 • Age: 34 yrs Acquired By Nanjing Xinbai
Autologous dendritic cell immunotherapies are developed for cancer treatment.

About Dendreon

Dendreon is a company based in Seal Beach (United States) founded in 1992 was acquired by Nanjing Xinbai in May 2018. It operates as a HealthTech, and Professional Services. Dendreon has raised $21.7 million across 3 funding rounds from investors including New York Life Insurance, Nanjing Xinbai and Healthcare Ventures. Dendreon offers products and services including Provenge and Cellular Therapy Manufacturing. Dendreon operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.

  • Headquarter Seal Beach, United States
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Dendreon Pharmaceuticals Llc
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $21.7 M (USD)

    in 3 rounds

  • Latest Funding Round
    $10 M (USD), Series C

    Oct 22, 1999

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Nanjing Xinbai

    & 1 more

    (May 25, 2018)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Dendreon

Dendreon offers a comprehensive portfolio of products and services, including Provenge and Cellular Therapy Manufacturing. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Provenge is used for advanced prostate cancer treatment.

Manufacturing support is provided for cellular therapy development.

People of Dendreon
Headcount 500-1000
Employee Profiles 106
Employee Profiles
People
Eric Smith
Immunotherapy Sales Specialist
People
Patrick Stinson
Corporate Account Director-southeast
People
Sarah Amato
Oncology Sales Specialist
People
Jessica Jeffares
Cell processor: Manufacturing Operations Associate

Unlock access to complete

Funding Insights of Dendreon

Dendreon has successfully raised a total of $21.7M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $10 million completed in October 1999. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series C — $10.0M
  • First Round
  • Investors Count 5
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 1999 Amount Series C - Dendreon Valuation

investors

Sep, 1997 Amount Series B - Dendreon Valuation

investors

Jun, 1996 Amount Series A - Dendreon Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Dendreon

Dendreon has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include New York Life Insurance, Nanjing Xinbai and Healthcare Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Biomedical investment financing and active management services.
Founded Year Domain Location
Private equity investments are backed by a single-family office firm.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Dendreon

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Dendreon

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Dendreon Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Dendreon

Dendreon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Targeted and immune-oncology drugs for cancer treatment are developed.
domain founded_year HQ Location
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
domain founded_year HQ Location
Small molecules are developed for cancer and skin disease treatments.
domain founded_year HQ Location
Cancer therapies are developed using selective pathway inhibitors.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Dendreon

Frequently Asked Questions about Dendreon

When was Dendreon founded?

Dendreon was founded in 1992 and raised its 1st funding round 4 years after it was founded.

Where is Dendreon located?

Dendreon is headquartered in Seal Beach, United States. It is registered at Seal Beach, California, United States.

Is Dendreon a funded company?

Dendreon is a funded company, having raised a total of $21.7M across 3 funding rounds to date.

What does Dendreon do?

Dendreon is engaged in the development and delivery of cellular therapies and immunotherapies aimed at improving patient outcomes. The company operates within the healthcare sector, specializing in biotechnology with a focus on innovative treatments like Provenge, an FDA-approved immunotherapy for prostate cancer. Strategic partnerships and research are leveraged to advance complex cell therapies. Manufacturing services are also provided to support other companies in bringing life-saving innovations to market.

Who are the top competitors of Dendreon?

Dendreon's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.

What products or services does Dendreon offer?

Dendreon offers Provenge and Cellular Therapy Manufacturing.

Who are Dendreon's investors?

Dendreon has 7 investors. Key investors include New York Life Insurance, Nanjing Xinbai, Healthcare Ventures, Sanderling Ventures, and Vulcan Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available